Related references
Note: Only part of the references are listed.Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event
Gerald G. Long et al.
TOXICOLOGIC PATHOLOGY (2008)
Nonclinical safety evaluation of muraglitazar, a novel PPARα/γ agonist
Crystal R. Waites et al.
TOXICOLOGICAL SCIENCES (2007)
Rodent carcinogenicity profile of the antidiabetic dual PPAR α and γ agonist muraglitazar
Sarah H. Tannehill-Gregg et al.
TOXICOLOGICAL SCIENCES (2007)
Tesaglitazar, a PPARα/γ agonist, induces interstitial mesenchyrnal cell DNA synthesis and fibrosarcornas in subcutaneous tissues in rats
Heike Hellmold et al.
TOXICOLOGICAL SCIENCES (2007)
Histopathology of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists
Jerry F. Hardisty et al.
TOXICOLOGIC PATHOLOGY (2007)
The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR)
MA Peraza et al.
TOXICOLOGICAL SCIENCES (2006)
Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action
Mark A. Dominick et al.
TOXICOLOGIC PATHOLOGY (2006)
Peroxisome proliferator-activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice
K Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Role of PPARγ and EGFR signalling in the urothelial terminal differentiation programme
CL Varley et al.
JOURNAL OF CELL SCIENCE (2004)
PPARγ signaling exacerbates mammary gland tumor development
E Saez et al.
GENES & DEVELOPMENT (2004)
Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists
C Grommes et al.
LANCET ONCOLOGY (2004)
An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats
K Arakawa et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2004)
Activation of peroxisome proliferator-activated receptor-γ reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells
CL Varley et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Thiazolidinedione use, fluid retention, and congestive heart failure - A consensus statement from the American Heart Association and American Diabetes Association
RW Nesto et al.
CIRCULATION (2003)
Peroxisome proliferator-activated receptor γ (PPARγ) ligands as bifunctional regulators of cell proliferation
HK Na et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Therapeutic potential of thiazolidinediones as anticancer agents
D Panigrahy et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2003)
Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone
JR Herman et al.
TOXICOLOGICAL SCIENCES (2002)
Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells
S Fauconnet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
PPARγ ligands suppress proliferation of human urothelial basal cells in vitro
S Kawakami et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2002)
Urinary tract calculi and thresholds in carcinogenesis
SM Cohen et al.
FOOD AND CHEMICAL TOXICOLOGY (2002)
Role of peroxisome proliferator-activated receptor γ and its ligands in non-neoplastic and neoplastic human urothelial cells
K Nakashiro et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance
CJ de Souza et al.
DIABETES (2001)
Share Paper
